Presepsin levels and COVID-19 severity: a systematic review and meta-analysis

Guarino, Matteo; Perna, Benedetta; Maritati, Martina; Remelli, Francesca; Trevisan, Caterina; Spampinato, Michele Domenico; Costanzini, Anna; Volpato, Stefano; Contini, Carlo; Giorgio, Roberto De

doi:10.1007/s10238-022-00936-8

Cited by 14 publications

(14 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some studies, the absence of a significant difference in those with positive cultures, may have been due to reasons such as the amount and quality of the sample, the severity of the infection, and the inadequacy of the laboratory. 6 According to the results of the systematic meta-analysis conducted by Guarino et al 19 a significant correlation was found between the severity of COVID-19 and presepsin level. Similarly, Kim et al 20 found a significant correlation between the severity of COVID-19 and presepsin level.…”

Section: Discussionmentioning

confidence: 99%

The evaluation of presepsin level and bacterial infection in neutropenic patients

Genç¹,

Çi̇fci̇²,

YALÇIN³

2023

JCHOR

View full text Add to dashboard Cite

Aim: Neutropenia is a life-threatening condition that is seen as a complication of chemotherapy, especially in cancer patients, if the patient is infected. Early treatment of the infection has aimportant effect on mortality. Our aim in this study is to investigate the usability of presepsin in terms of diagnosis of bacterial infection in patients who are neutropenic after chemotherapy. Methods: In this study, presepsin, erythrocyte sedimentation rate (ESR), CRP (C-reactive protein), and procalcitonin were measured in 25 neutropenic patients, and a comparison was made between those who were culture positive and negative, those who had a fever and those who did not. In addition, presepsin and CRP values were compared with the control group of 22 people. Results: Presepsin, CRP, ESR and procalcitonin were significantly higher in those who did not reproduce in each culture (p<0.001, p=0.003, p=0.026, p<0.01, respectively) compared to those who did not have a fever (p<0.001, p<0.001, p < 0.001, p=0.019, respectively). Conclusion: Presepsin has the potential to be used in the early evaluation of bacterial infection in neutropenic patients. However, more work should be done on this issue.

show abstract

Section: Discussionmentioning

confidence: 99%

The evaluation of presepsin level and bacterial infection in neutropenic patients

Genç¹,

Çi̇fci̇²,

YALÇIN³

2023

JCHOR

View full text Add to dashboard Cite

show abstract

“…Presepsin is a biomarker that has been studied in relation to sepsis, a potentially life-threatening condition that occurs when the body’s response to infection causes damage to its own tissues and organs. There is research evidence that suggests that presepsin levels may be elevated in individuals with severe COVID-19, particularly those who develop sepsis as a complication of the disease [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Monitoring the Coagulation Profile of COVID-19 Patients Using Standard and ClotPro® Hemostasis Tests

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: Coagulation disorders during COVID-19 infection are associated with a poorer prognosis and higher disease severity because thrombosis and inflammation are two processes that interfere with each other. A very important issue for clinicians is timely and adequate hemostasis and inflammation monitoring to prevent and treat potentially lethal consequences. The aim of this study was to identify specific hemostatic parameters that are associated with a higher risk of intrahospital mortality. Materials and Methods: This study was approved by the Ethics Committee of the Clinical Center Nis in Serbia. One hundred and forty-two patients presented with COVID-19 ARDS and were admitted to the ICU in the Clinic for Anesthesiology at the Clinical Center Nis from 14 April 2020 to 25 May 2020. Upon admission, blood was collected for biochemical and coagulation testing. The data obtained were analyzed using the Statistical Package for Social Sciences (SPSS v. 25, Chicago, IL, USA). Results: Among all the parameters assessed, older age; increased levels of fibrinogen, INR, D-dimer, and presepsin; and higher results in the platelet aggregation tests (aggregation induced by adenosine diphosphate based on the ADP test (AU/min), aggregation induced by arachidonic acid based on the ASPI test (AU/min), and aggregation induced by thrombin based on the TRAP test (AU/min)) and some assays of the viscoelastic test (clot amplitude after 5 min in the extrinsic coagulation pathway based on the A5 EX-test (mm), clot amplitude after 10 min in the extrinsic coagulation pathway based on the A10 EX-test (mm), clot amplitude after 5 min regarding functional fibrinogen based on the A5 FIB-test (mm), clot amplitude after 10 min regarding functional fibrinogen based on the A10 FIB-test (mm), and maximum clot firmness based on the MCF FIB-test (mm)); and lower values of viscoelastic clotting time in the extrinsic coagulation pathway based on the CT EX-test (s) were significantly correlated with mortality. In the multivariate analysis, D-dimer levels above 860 ng/mL, higher TRAP test value bins, and values above the normal reference range of the A10 FIB test were found to be independent predictors of mortality. Conclusions: Sophisticated hemostasis parameters can contribute to early risk assessment, which has initially been performed only on the basis of patients’ clinical status. Hypercoagulability is the main coagulation disorder in COVID-19 infection.

show abstract

“…They found that PSP levels were increased by 2.74-fold in COVID-19 patients with severe illness compared to those without. Guarino et al [62] published a meta-analysis of data from 707 patients from 15 studies, and they found that the pooled mean difference of PSP levels between high-and low-severity COVID-19 patients was 441.70 pg/ml (95%CI: 150.40-732.99 pg/ml). In another interesting study published by Dell'Aquila and colleagues [63], in a population of COVID-19 patients with acute respiratory failure in an emergency department, PSP was accurate predictor of 30-day mortality.…”

Section: Presepsin and Covid-19mentioning

confidence: 99%

Presepsin in Critical Illness: Current Knowledge and Future Perspectives

Formenti,

Gotti,

Palmieri

et al. 2024

Preprint

View full text Add to dashboard Cite

The accurate identification of bacterial infections is critical for effective treatment in intensive care units (ICUs), yet current diagnostic methods face limitations in sensitivity and specificity, along-side cost and accessibility issues. Consequently, there's a pressing need for a marker that is economically feasible, rapid, and reliable. Presepsin (PSP), also known as soluble CD14 subtype (sCD14-ST), has emerged as a promising biomarker for early sepsis diagnosis. PSP, derived from soluble CD14, reflects the activation of monocytes/macrophages in response to bacterial infec-tions. It has shown potential as a marker of cellular immune response activation against patho-gens, with plasma concentrations increasing during bacterial infections and decreasing post-antibiotic treatment. Unlike traditional markers such as procalcitonin (PCT) and C-reactive protein (CRP), PSP specifically indicates monocyte/macrophage activation in bacterial infections. While limited studies in critical illness have explored PSP's role in sepsis, its diagnostic accuracy varies with threshold values, impacting sensitivity and specificity. Recent meta-analyses suggest PSP's diagnostic potential for sepsis, yet its standalone effectiveness in ICU infection management remains uncertain. This review provides a comprehensive overview of PSP's utility in ICU set-tings, including its diagnostic accuracy, prognostic value, therapeutic implications, challenges, and future directions.

show abstract

Presepsin levels and COVID-19 severity: a systematic review and meta-analysis

Cited by 14 publications

References 39 publications

The evaluation of presepsin level and bacterial infection in neutropenic patients

The evaluation of presepsin level and bacterial infection in neutropenic patients

Monitoring the Coagulation Profile of COVID-19 Patients Using Standard and ClotPro® Hemostasis Tests

Presepsin in Critical Illness: Current Knowledge and Future Perspectives

Contact Info

Product

Resources

About